TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02524405

Intervention type: OTHER
Intervention: Pittsburgh Compound B [11C]-PIB
Description: This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.

Intervention type: OTHER
Intervention: Pittsburgh Compound B [11C]-PIB
Description: This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.

Intervention type: OTHER
Intervention: Pittsburgh Compound B [11C]-PIB
Description: This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.

Intervention type: OTHER
Intervention: Pittsburgh Compound B [11C]-PIB
Description: This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.

Intervention type: OTHER
Intervention: Pittsburgh Compound B [11C]-PIB
Description: This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
Study: NCT04406220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small clog size
Description: Participants will be randomized to run in small clogs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large clog size
Description: Participants will be randomized to run in large clogs
Study: NCT02297191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar Interfascial Plane Block
Description: All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~1. Ultrasound images will be saved using the nomenclature TLIP Anatomy~2. Photos will only include surface anatomy of the low-to-mid back.~3. Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Study: NCT03838146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Types of Exercise
Description: moderate intensity exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Types of Exercise
Description: moderate intensity exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Types of Exercise
Description: moderate intensity exercise
Study: NCT01758120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone plus cyclophosphamide
Description: 1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control
Study: NCT02091245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-330
Study: NCT03066596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRAGMATIC
Description: Provider educational seminar, EHR prompt, outreach-worker care coordination
Study: NCT01758120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone alone
Description: 1. prednisone alone: prednisone(0.5mg/kg/day\*6 months);~2. supportive care,including ACE-I or ARBs and blood pressure control
Study: NCT00938574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atu027
Study: NCT03528629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Description: Zolbetuximab will be administered as a 2-hour intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Description: Zolbetuximab will be administered as a 2-hour intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Description: Zolbetuximab will be administered as a 2-hour intravenous infusion.
Study: NCT02820857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfiri-bevacizumab
Description: Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfiri
Description: Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
Study: NCT03417843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUSRA RF electrode
Description: At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces
Study: NCT04441242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambient lighting
Description: Use of ambient lighting (75-150 lux) in endoscopy room.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low lighting
Description: Use of low lighting (\<75 lux) in endoscopy room.
Study: NCT02621944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All participants will receive an MRI between 7-12 days of age.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All participants will receive an MRI between 7-12 days of age.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All participants will receive an MRI between 7-12 days of age.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: All participants will receive pharmacokinetics to test the amount of melatonin in the blood.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
Study: NCT04345523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and derivatives.
Description: Administration of fresh plasma from donor immunized against COVID-19
Study: NCT00834678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 100 or 120 mg/m2 IV on days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 100 or 150 mg po on days 5 - 21 of each 28 day cycle
Study: NCT04345523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care for the treatment of COVID-19 in hospitalized patients
Study: NCT01227356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib and pegylated interferon
Description: imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
Study: NCT00834678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib
Description: 150 mg po daily (days 1 - 28 of 28 day cycle)
Study: NCT02876094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: dose-response
Study: NCT03237078

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128
Description: Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
Study: NCT01346969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXC 001
Description: Single-dose administered by injection four different times

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EXC 001
Description: Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EXC 001
Description: Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EXC 001
Description: Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
Study: NCT03540030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toradol
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03274102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Concomitant administration of EV71 vaccine with EPI vaccines
Description: 1. The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single injection of EPI vaccine
Description: 1. The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
Study: NCT03540030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regional block
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV lidocaine
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03274102

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 Vaccine only
Description: The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
Study: NCT03540030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vecuronium
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03986606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSB205
Description: PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
Study: NCT03540030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT02708862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoxygenation
Description: After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
Study: NCT03439787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution
Description: 10 ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9 %
Description: 10 ml
Study: NCT04127942

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: platelet-rich plasma injection therapy of TMD
Description: The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma injection therapy of TMD
Description: The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
Study: NCT00447005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: AG-013736 5mg twice daily \[BID\]
Study: NCT02621944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
Study: NCT04011033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT cells
Description: 5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinated Interleukin-2
Description: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAE/TACE
Description: TAE/TACE will be conducted to all patients at 0th week and 4th week.
Study: NCT02621944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurological Outcome Assessment
Description: All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurological Outcome Assessment
Description: All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
Study: NCT04011033

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAE/TACE
Description: TAE/TACE will be conducted to all patients at 0th week and 4th week.
Study: NCT02621944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurological Outcome Assessment
Description: All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
Study: NCT01782274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
Study: NCT04476147

Intervention type: OTHER
Intervention: Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.
Description: This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
Study: NCT01823341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump suspension algorithm
Description: The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
Study: NCT04455048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervicothoracic thrust manipulation
Description: The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cervicothoracic thrust manipulation sham
Description: The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
Study: NCT03307811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 22 gauge needle liver biopsy
Description: EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
Study: NCT04330495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hidroxicloroquina
Description: Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
Study: NCT00842582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
Study: NCT01648933

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Rubidium PET
Description: Myocardial Perfusion Imaging
Study: NCT03340779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
Study: NCT00842582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
Study: NCT00232479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab, docetaxel and carboplatin in dose dense regimen
Description: trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
Study: NCT00063258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tarceva (OSI-774)
Description: 150 mg/day, starting day 1 and stopping night prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.